KR102142311B1 - Skin external composition comprising tangeretin - Google Patents
Skin external composition comprising tangeretin Download PDFInfo
- Publication number
- KR102142311B1 KR102142311B1 KR1020120146540A KR20120146540A KR102142311B1 KR 102142311 B1 KR102142311 B1 KR 102142311B1 KR 1020120146540 A KR1020120146540 A KR 1020120146540A KR 20120146540 A KR20120146540 A KR 20120146540A KR 102142311 B1 KR102142311 B1 KR 102142311B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- skin
- present
- green tea
- citrus peel
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 143
- ULSUXBXHSYSGDT-UHFFFAOYSA-N tangeretin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 ULSUXBXHSYSGDT-UHFFFAOYSA-N 0.000 title claims abstract description 106
- IECRXMSGDFIOEY-UHFFFAOYSA-N Tangeretin Natural products COC=1C(OC)=C(OC)C(OC)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C=C1 IECRXMSGDFIOEY-UHFFFAOYSA-N 0.000 title claims abstract description 50
- 239000000284 extract Substances 0.000 claims abstract description 72
- 235000020971 citrus fruits Nutrition 0.000 claims abstract description 67
- 241000207199 Citrus Species 0.000 claims abstract description 66
- 235000020688 green tea extract Nutrition 0.000 claims abstract description 54
- 229940094952 green tea extract Drugs 0.000 claims abstract description 54
- 239000002537 cosmetic Substances 0.000 claims abstract description 35
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 26
- 206010015150 Erythema Diseases 0.000 claims abstract description 24
- 239000004480 active ingredient Substances 0.000 claims abstract description 22
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims abstract description 13
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000003963 antioxidant agent Substances 0.000 claims description 27
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 24
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 13
- 235000011187 glycerol Nutrition 0.000 claims description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 2
- 229940030275 epigallocatechin gallate Drugs 0.000 abstract description 7
- 235000013402 health food Nutrition 0.000 abstract description 3
- 230000009759 skin aging Effects 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 description 23
- 235000006708 antioxidants Nutrition 0.000 description 22
- -1 hydroxy radicals Chemical class 0.000 description 18
- 230000000694 effects Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000006071 cream Substances 0.000 description 13
- 239000006210 lotion Substances 0.000 description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 12
- 239000003755 preservative agent Substances 0.000 description 11
- 239000008213 purified water Substances 0.000 description 10
- 230000002195 synergetic effect Effects 0.000 description 9
- 238000007796 conventional method Methods 0.000 description 8
- 231100000321 erythema Toxicity 0.000 description 8
- 229920002125 Sokalan® Polymers 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 6
- 229930003268 Vitamin C Natural products 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 235000019154 vitamin C Nutrition 0.000 description 6
- 239000011718 vitamin C Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 229960004063 propylene glycol Drugs 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 229920002498 Beta-glucan Polymers 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 3
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 150000002213 flavones Chemical class 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 235000009569 green tea Nutrition 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 229940113124 polysorbate 60 Drugs 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- RJURRZFUWSRXDY-UHFFFAOYSA-N 1-phenoxyethanol Chemical compound CC(O)OC1=CC=CC=C1.CC(O)OC1=CC=CC=C1 RJURRZFUWSRXDY-UHFFFAOYSA-N 0.000 description 2
- NALUDDWNDBCDQS-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound C(C)C(O)(C(O)CO)CCCCCC.C(C)C(O)(C(O)CO)CCCCCC NALUDDWNDBCDQS-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920000289 Polyquaternium Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940081733 cetearyl alcohol Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- IMOYOUMVYICGCA-UHFFFAOYSA-N 2-tert-butyl-4-hydroxyanisole Chemical compound COC1=CC=C(O)C=C1C(C)(C)C IMOYOUMVYICGCA-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- PBFGMXZRJIUGKU-UHFFFAOYSA-N 3-decanoyloxybutyl decanoate Chemical compound CCCCCCCCCC(=O)OCCC(C)OC(=O)CCCCCCCCC PBFGMXZRJIUGKU-UHFFFAOYSA-N 0.000 description 1
- LFESLSYSZQYEIZ-UHFFFAOYSA-N 3-octanoyloxybutyl octanoate Chemical compound CCCCCCCC(=O)OCCC(C)OC(=O)CCCCCCC LFESLSYSZQYEIZ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108030002440 Catalase peroxidases Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Natural products O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940114374 butylene glycol dicaprylate Drugs 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 229950009789 cetomacrogol 1000 Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 125000003450 decanoic acid ester group Chemical group 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229930182496 polymethoxyflavone Natural products 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000010415 tidying Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 텐저레틴을 유효성분으로 함유하는 피부 외용제 조성물을 제공한다. 또한 본 발명은 텐저레틴 및 EGCG를 함유하는 피부 외용제 조성물을 제공한다. 또한 본 발명은 텐저레틴을 함유하는 감귤피추출물을 유효성분으로 포함하는 피부 외용제 조성물을 제공한다. 또한, 본 발명은 텐저레틴을 함유하는 감귤피추출물에 EGCG(Epigallocatechin gallate)를 함유하는 녹차 추출물을 더 포함하는 피부 외용제 조성물을 제공한다. 본 발명의 조성물은 항산화 효과가 우수하여 화장료 조성물, 약학 또는 건강식품 조성물로 응용 가능하다. 또한, 본 발명의 조성물은 피부 홍반 방지, 피부톤 개선, 피부 노화 방지 효과도 우수하다.The present invention provides a composition for external application for skin containing tenseretin as an active ingredient. In addition, the present invention provides a composition for external application for skin containing tenseretin and EGCG. In addition, the present invention provides a composition for external application for skin comprising a citrus peel extract containing tangeretin as an active ingredient. In addition, the present invention provides a composition for external application for skin further comprising a green tea extract containing EGCG (Epigallocatechin gallate) in a citrus peel extract containing tangeretin. The composition of the present invention is excellent in antioxidant effect and can be applied as a cosmetic composition, pharmaceutical or health food composition. In addition, the composition of the present invention is excellent in preventing skin erythema, improving skin tone, and preventing skin aging.
Description
본 발명은 텐저레틴을 함유하는 피부 외용제 조성물에 관한 것이다. 또한 본 발명은 텐저레틴 및 EGCG를 함유하는 피부 외용제 조성물에 관한 것이다.The present invention relates to a composition for external application for skin containing tenseretin. In addition, the present invention relates to a composition for external application for skin containing tenseretin and EGCG.
인간을 포함한 모든 호기성 생물체는 산소를 이용하는 에너지 대사 과정에서 항상 발생하는 활성 산소의 상해에 대하여 근본적으로는 자기 방어능을 초월한 활성 산소의 생성은 최근 성인병이라 알려져 관절염, 순환기 장애뿐만 아니라 치매 등과 같은 여러 질환의 원인이 되고 있다. All aerobic organisms, including humans, are known as adult diseases in recent years, and the generation of free radicals beyond self-defense is known as arthritis, circulatory disorders, as well as dementia. It is causing the disease.
흔히 유해산소라고 알려진 활성산소는 가장 안정한 형태의 산소인 삼중항산소(3O2)가 산화, 화원 과정에서 환원되어 생성되는 일중항산소인 슈퍼옥사이드 음이온(1O2 -)과 과산화수소(H2O2), 하이드록시라디칼(·OH)과 같은 짝짓지 않은 상태의 자유 라디칼로서, 이들은 단백질, DNA, 효소 또는 T세포와 같은 면역계통의 인자를 손상시켜 질환을 일으킨다. Radicals commonly known as free radical is the most stable form of the oxygen in the triplet oxygen (3 O 2) is the superoxide anion singlet oxygen that is generated is reduced in the oxidation, Garden process (1 O 2 -) and hydrogen peroxide (H 2 As unpaired free radicals such as O 2 ) and hydroxy radicals (·OH), they cause diseases by damaging factors of the immune system such as proteins, DNA, enzymes or T cells.
이러한 이유로 항산화제의 개발 연구가 활발히 진행되어 효소 계열의 예방적 항산화제인 슈퍼옥사이드 디스뮤타제(Superoxide dismutase), 카탈라제(Catalase), 글루타티온페록시다제(Glutathioneperoxidase) 등과 같은 항산화효소와 천연 항산화제인 비타민E, 비타민 C, 카로테노이드(Carotenoid), 글루타티온(Glutathione) 및 합성 항산화제인 부틸히드록시아니졸(t-Butyl-4-hydroxyanisole: BHA), 디부틸히드록시톨루엔(3,5-(t-Butyl)-4-hydroxytoluene: BHT) 등 많은 항산화제가 알려져 있다. 그러나, 항산화효소는 나이가 들어서 늙어감에 따라 활성산소에 대한 방어능력이 감소되며, 합성 항산화제 경우 그의 변이원성 및 독성이 지적되면서 보다 안전하고 효력이 강한 천연 항산화제의 개발이 절실히 요청되고 있는 실정이다. 본 발명자들은 우수한 항산화 활성을 가지는 천연물을 스크리닝하던 중에 본 발명을 완성하게 되었다.For this reason, the development of antioxidants has been actively conducted, and antioxidant enzymes such as superoxide dismutase, catalase, and glutathioneperoxidase, which are enzyme-based prophylactic antioxidants, and vitamin E, a natural antioxidant. , Vitamin C, carotenoid, glutathione and synthetic antioxidants, butylhydroxyanisole (t-Butyl-4-hydroxyanisole: BHA), dibutylhydroxytoluene (3,5-(t-Butyl)- Many antioxidants are known, such as 4-hydroxytoluene: BHT). However, as antioxidant enzymes age and age, the ability to defend against active oxygen decreases, and in the case of synthetic antioxidants, their mutagenicity and toxicity are pointed out, so the development of safer and stronger natural antioxidants is urgently required. to be. The present inventors have completed the present invention while screening for natural products having excellent antioxidant activity.
본 발명은 상기한 문제점을 해결하기 위해 텐저레틴(tangeretin)을 함유하는 피부 외용제 조성물 또는 텐저레틴 및 EGCG를 포함하여 항산화 활성을 가지는 조성물을 제공하는 것을 목적으로 한다.
An object of the present invention is to provide a composition for external application for skin containing tangeretin or a composition having antioxidant activity including tangeretin and EGCG in order to solve the above problems.
본 발명은 텐저레틴을 유효성분으로 함유하는 피부 외용제 조성물을 제공한다. 또한 본 발명은 텐저레틴 및 EGCG를 함유하는 피부 외용제 조성물을 제공한다. 또한 본 발명은 텐저레틴을 함유하는 감귤피추출물을 유효성분으로 포함하는 피부 외용제 조성물을 제공한다. 또한, 본 발명은 텐저레틴을 함유하는 감귤피추출물에 EGCG(Epigallocatechin gallate)를 함유하는 녹차 추출물을 더 포함하는 피부 외용제 조성물을 제공한다.The present invention provides a composition for external application for skin containing tenseretin as an active ingredient. In addition, the present invention provides a composition for external application for skin containing tenseretin and EGCG. In addition, the present invention provides a composition for external application for skin comprising a citrus peel extract containing tangeretin as an active ingredient. In addition, the present invention provides a composition for external application for skin further comprising a green tea extract containing EGCG (Epigallocatechin gallate) in a citrus peel extract containing tangeretin.
본 발명의 피부 외용제 조성물은 항산화 효과가 우수하여 화장료 조성물, 약학 또는 건강식품 조성물로 응용 가능하다. 또한, 본 발명의 조성물은 피부 홍반 방지, 피부톤 개선, 피부 노화 방지 효과도 우수하다.
The composition for external application for skin of the present invention has excellent antioxidant effect and can be applied as a cosmetic composition, pharmaceutical or health food composition. In addition, the composition of the present invention is excellent in preventing skin erythema, improving skin tone, and preventing skin aging.
도 1은 텐저레틴을 포함하는 감귤피 추출물을 얻는 공정도를 나타낸 것이다.
도 2는 감귤피 추출물, 녹차 추출물 및 비타민 C를 농도 변화에 따라 DPPH 측정하여 흡광도 값을 나타낸 것이다.
도 3은 감귤피 추출물, 녹차 추출물을 사용하였을 때 DPPH 측정을 하여 항산화 효과 및 감귤피 추출물과 녹차 추출물 병용시의 시너지 효과를 보인 실험결과를 나타낸 것이다.
도 4는 텐저레틴과 EGCG의 항산화 시너지 효과의 시험결과를 나타낸 도이다.1 shows a process chart of obtaining a citrus peel extract containing tangeretin.
Figure 2 shows the absorbance value by measuring DPPH according to the concentration change of citrus peel extract, green tea extract, and vitamin C.
3 shows the experimental results showing the antioxidant effect and synergistic effect when citrus peel extract and green tea extract are used in combination by measuring DPPH when citrus peel extract and green tea extract are used.
4 is a diagram showing the test results of the antioxidant synergistic effect of tangeretin and EGCG.
본 발명의 피부 외용제 조성물은 텐저레틴을 유효성분으로 함유한다. 또한 본 발명은 텐저레틴 및 EGCG를 함유하는 피부 외용제 조성물에 관한 것이다. 또한 본 발명은 텐저레틴을 포함하는 감귤피추출물을 유효성분으로 포함하는 피부 외용제 조성물에 관한 것이다. 또한, 본 발명은 텐저레틴을 포함하는 감귤피추출물에 EGCG(Epigallocatechin gallate)를 포함하는 녹차 추출물을 더 포함하는 피부 외용제 조성물에 관한 것이다.
The composition for external application for skin of the present invention contains tenseretin as an active ingredient. In addition, the present invention relates to a composition for external application for skin containing tenseretin and EGCG. In addition, the present invention relates to a composition for external application for skin comprising a citrus skin extract containing tangeretin as an active ingredient. In addition, the present invention relates to a composition for external application for skin further comprising a green tea extract containing EGCG (Epigallocatechin gallate) in a citrus peel extract containing tangeretin.
본 발명의 피부 외용제 조성물은 텐저레틴을 함유하는 감귤피추출물을 유효성분으로 포함한다. 또한, 본 발명은 텐저레틴을 함유하는 감귤피추출물에 EGCG를 함유하는 녹차 추출물을 더 포함하는 것으로서, 항산화 활성을 갖는 피부 외용제 조성물을 제공한다.
The composition for external application for skin of the present invention comprises a citrus peel extract containing tangeretin as an active ingredient. In addition, the present invention further comprises a green tea extract containing EGCG in a citrus peel extract containing tangeretin, and provides a composition for external application for skin having antioxidant activity.
이하 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명에서 사용하는 텐저레틴(Tangeretin)은 시트러스 플라보노이드계로 O-폴리메톡실레이트 플라본(O-polymethoxylated flavones)의 구조를 가진다. 본 발명에서 사용하는 텐저레틴(tangeretin)은 시트러스 플라보노이드계로 O-폴리메톡실레이트 플라본(O-polymethoxylated flavones)의 구조를 가진다. 플라본(flavones)류 중 폴리메톡실레이트 플라본(polymethoxyflavone)류는 다른 야채, 과일에는 거의 없고 감귤류의 특징적인 성분으로 플라보노이드(flavonoid)에 5개의 메톡시가 치환되어 있는 물질이다. 따라서, 텐저레틴은 하기의 화학식 1로 표현된다.Tangeretin used in the present invention is a citrus flavonoid system and has a structure of O-polymethoxylated flavones. Tangeretin used in the present invention is a citrus flavonoid system and has a structure of O-polymethoxylated flavones. Among the flavones, polymethoxyflavones are rarely found in other vegetables and fruits, and are a characteristic component of citrus fruits, and are a substance in which 5 methoxys are substituted in flavonoids. Therefore, tangeretin is represented by the following formula (1).
본 발명에서 사용하는 녹차추출물은 EGCG(Epigallocatechin gallate) 등 카테킨류를 포함하고 EGCG는 탄닌 또는 폴리페놀의 구성성분으로서 강력한 항산화 효과를 가지며, 하기 화학식 2의 구조로 표현된다.The green tea extract used in the present invention contains catechins such as EGCG (Epigallocatechin gallate), and EGCG has a strong antioxidant effect as a constituent of tannin or polyphenol, and is represented by the structure of Formula 2 below.
본 발명의 일 실시예에서 상기 텐저레틴은 감귤피 추출물로부터 수득된 것일 수 있다. 본 발명의 다른 일 실시예에서 상기 텐저레틴은 텐저레틴을 포함하는 감귤피 추출물로서 함유될 수 있다. 상기 감귤피 추출물은 텐저레틴을 포함하는 천연 추출물로서 다수의 유용성 성분을 함유하는 혼합물이다.In one embodiment of the present invention, the tangeretin may be obtained from citrus peel extract. In another embodiment of the present invention, the tangeretin may be contained as a citrus peel extract containing tenseretin. The citrus peel extract is a natural extract containing tenseretin, and is a mixture containing a plurality of oil-soluble ingredients.
본 발명의 일 실시예에서 상기 EGCG는 녹차 추출물로부터 수득된 것일 수 있다. 본 발명의 다른 일 실시예에서 상기 EGCG는 EGCG를 포함하는 녹차 추출물로서 함유될 수 있다. 상기 녹차 추출물은 EGCG를 포함하는 천연 추출물로서 다수의 유용성 성분을 함유하는 혼합물이다.In an embodiment of the present invention, the EGCG may be obtained from green tea extract. In another embodiment of the present invention, the EGCG may be contained as a green tea extract containing EGCG. The green tea extract is a natural extract containing EGCG and is a mixture containing a number of oil-soluble ingredients.
본 발명의 일 실시예에서 상기 추출물은 원료를 유기용매에 침적하여 추출한 후 여과, 감압 및 농축하여 얻은 농축물을 사용할 수 있다. 또는 상기 농축물을 다시 건조시켜 제조한 침체, 전제, 정기 및 유동 엑기스를 사용할 수 있다. 상기 침적물은 감귤피 또는 녹차를 용매를 사용하여 냉침, 페르콜레이션(percolation), 온침 등의 임의의 방법에 의해 침적하여 유효 성분을 함유한 침적물을 얻을 수 있다. 상기 유기 용매는 C1~C4의 무수 또는 함수 알코올, 아세톤, 에틸아세테이트, 클로로포름, 글리세린, 프로필렌글리콜 및 부틸렌글리콜 중에서 선택된 하나 이상일 수 있으나, 이에 제한되지는 않는다In one embodiment of the present invention, the extract may be a concentrate obtained by filtration, reduced pressure, and concentration after extracting the raw material by immersing it in an organic solvent. Alternatively, stagnation, whole agent, regular and flowing extract prepared by drying the concentrate may be used. The deposit can be obtained by depositing citrus peel or green tea using a solvent by an arbitrary method such as cold needle, percolation, warm needle, etc. to obtain a deposit containing the active ingredient. The organic solvent may be one or more selected from C 1 ~ C 4 anhydrous or hydrous alcohol, acetone, ethyl acetate, chloroform, glycerin, propylene glycol, and butylene glycol, but is not limited thereto.
상기 감귤피는 자연 건조 또는 강제 건조 등 임의의 방법으로 건조하여 잘게 자른 후 사용할 수 있다.The citrus peel can be used after drying by any method such as natural drying or forced drying, and then finely chopped.
본 발명은 텐저레틴을 유효성분으로 함유하는 항산화용 피부외용제 조성물에 관한 것이다. 또한 본 발명은 텐저레틴 및 EGCG를 함유하는 항산화용 피부 외용제 조성물에 관한 것이다. 또한 본 발명은 텐저레틴을 포함하는 감귤피추출물을 유효성분으로 포함하는 항산화용 피부 외용제 조성물에 관한 것이다. 또한, 본 발명은 텐저레틴을 포함하는 감귤피추출물에 EGCG(Epigallocatechin gallate)를 포함하는 녹차 추출물을 더 포함하는 항산화용 피부 외용제 조성물에 관한 것이다.The present invention relates to a composition for external skin for antioxidants containing tenseretin as an active ingredient. In addition, the present invention relates to a composition for external application for skin for antioxidants containing tangeretin and EGCG. In addition, the present invention relates to a composition for external application for skin for antioxidants comprising a citrus skin extract containing tangeretin as an active ingredient. In addition, the present invention relates to a composition for external application for skin for antioxidant further comprising a green tea extract containing EGCG (Epigallocatechin gallate) in a citrus peel extract containing tangeretin.
본 발명의 항산화용 피부 외용제 조성물에 있어서 상기 텐저레틴은 조성물 총 중량에 대하여 0.001 ~ 10 중량%로 함유할 수 있다. 상기 텐저레틴이 0.001 중량% 미만인 경우 항산화 효과가 거의 없으며 10 중량%를 초과하는 경우에는 변취 등 화장품 변성의 우려가 있고 화장품 제형의 점도 조절이 쉽지 않으며 과량 사용시 피부의 자극을 유발할 수도 있다. In the composition for external application for skin for antioxidants of the present invention, the tangeretin may be contained in an amount of 0.001 to 10% by weight based on the total weight of the composition. If the tangeretin is less than 0.001% by weight, there is little antioxidant effect, and if it exceeds 10% by weight, there is a concern of cosmetic deterioration such as off-flavor, and it is not easy to adjust the viscosity of the cosmetic formulation, and when used in excess, it may cause skin irritation.
본 발명의 항산화용 피부 외용제 조성물에 있어서 상기 EGCG는 조성물 총 중량에 대하여 0.001 ~ 20 중량%로 함유할 수 있다. 상기 EGCG가 0.001 중량% 미만인 경우 항산화 효과가 거의 없으며 20 중량%를 초과하는 경우에는 변취 등 화장품 변성의 우려가 있고 화장품 제형의 점도 조절이 쉽지 않으며 에멀젼 제형 제조시 전상이 일어나기 쉽기 때문에 화장료 제형으로서 개발하기 어렵고 생산 경제성도 떨어지게 된다.In the composition for external application for skin for antioxidants of the present invention, the EGCG may be contained in an amount of 0.001 to 20% by weight based on the total weight of the composition. When the EGCG is less than 0.001% by weight, there is little antioxidant effect, and when it exceeds 20% by weight, there is a concern of cosmetic deterioration such as off-flavor, it is not easy to adjust the viscosity of the cosmetic formulation, and it is easy to burn out when manufacturing an emulsion formulation. It is difficult to do and the economics of production are also poor.
본 발명의 항산화용 피부 외용제 조성물에 있어서 상기 텐저레틴(tangeretin)을 함유하는 감귤피 추출물은 조성물 총 중량에 대하여 0.001 ~ 10 중량%로 함유될 수 있다. 감귤피 추출물이 0.001 중량% 미만으로 포함되면 항산화 효과가 거의 없다.In the composition for external application for skin for antioxidants of the present invention, the citrus peel extract containing tangeretin may be contained in an amount of 0.001 to 10% by weight based on the total weight of the composition. If the citrus peel extract is contained in an amount of less than 0.001% by weight, there is almost no antioxidant effect.
본 발명의 항산화용 피부 외용제 조성물에 있어서 상기 EGCG를 포함하는 녹차 추출물은 조성물 총 중량에 대하여 0.001 ~ 99.9 중량%로 포함될 수 있다. 녹차 추출물이 0.001 중량% 미만으로 포함되면 항산화 효과가 거의 없다. In the composition for external application for skin for antioxidants of the present invention, the green tea extract containing EGCG may be included in an amount of 0.001 to 99.9% by weight based on the total weight of the composition. When the green tea extract is contained in an amount of less than 0.001% by weight, there is almost no antioxidant effect.
본 발명의 항산화용 피부 외용제 조성물의 항산화 효과는 텐저레틴을 함유하는 감귤피 추출물 및 EGCG를 함유하는 녹차 추출물의 복합 추출물에서 더 크게 나타나며, 이는 감귤피 추출물에 함유된 텐저레틴과 녹차 추출물에 함유된 EGCG의 시너지 효과에 의한 것이다.
The antioxidant effect of the composition for external application for skin for antioxidant of the present invention is greater in the complex extract of the citrus peel extract containing tangeretine and the green tea extract containing EGCG, which is contained in the tangeretine and green tea extract contained in the citrus peel extract. This is due to the synergistic effect of EGCG.
본 발명은 텐저레틴을 유효성분으로 함유하는 피부 홍반 방지용 피부외용제 조성물에 관한 것이다. 또한 본 발명은 텐저레틴 및 EGCG를 함유하는 피부 홍반 방지용 피부 외용제 조성물에 관한 것이다. 또한 본 발명은 텐저레틴을 포함하는 감귤피추출물을 유효성분으로 포함하는 피부 홍반 방지용 피부 외용제 조성물에 관한 것이다. 또한, 본 발명은 텐저레틴을 포함하는 감귤피추출물에 EGCG(Epigallocatechin gallate)를 포함하는 녹차 추출물을 더 포함하는 피부 홍반 방지용 피부 외용제 조성물에 관한 것이다.The present invention relates to a composition for external application for skin for preventing skin erythema containing tenseretin as an active ingredient. In addition, the present invention relates to a composition for external application for skin for preventing skin erythema containing tangeretin and EGCG. In addition, the present invention relates to a composition for external application for skin for preventing skin erythema comprising a citrus skin extract containing tangeretin as an active ingredient. In addition, the present invention relates to a composition for external application for skin for preventing skin erythema further comprising a green tea extract containing EGCG (Epigallocatechin gallate) in a citrus peel extract containing tangeretin.
본 발명의 피부 홍반 방지용 피부 외용제 조성물에 있어서 상기 텐저레틴은 조성물 총 중량에 대하여 0.001 ~ 10 중량%로 함유할 수 있다. 상기 텐저레틴이 0.001 중량% 미만인 경우 홍반 방지 효과가 거의 없으며 10 중량%를 초과하는 경우, 조성물의 안정성 및 안전성을 모두 만족할 수 없으며, 비용 대비 효과의 측면에서도 상기 범위로 포함하는 것이 적절할 수 있다.In the composition for external application for skin for preventing skin erythema of the present invention, the tangeretin may be contained in an amount of 0.001 to 10% by weight based on the total weight of the composition. When the tangeretin is less than 0.001% by weight, there is little effect of preventing erythema, and when it exceeds 10% by weight, both the stability and safety of the composition cannot be satisfied, and it may be appropriate to include in the above range in terms of cost-effectiveness.
본 발명의 피부 홍반 방지용 피부 외용제 조성물에 있어서 상기 EGCG는 조성물 총 중량에 대하여 0.001 ~ 10 중량%로 함유할 수 있다. 상기 EGCG가 0.001 중량% 미만인 경우 홍반 방지 효과가 거의 없으며 10 중량%를 초과하는 경우에는 변취 등 화장품 변성의 우려가 있고 화장품 제형의 점도 조절이 쉽지 않으며 과량 사용시 피부의 자극을 유발할 수도 있다. In the composition for external application for skin for preventing skin erythema of the present invention, the EGCG may be contained in an amount of 0.001 to 10% by weight based on the total weight of the composition. When the EGCG is less than 0.001% by weight, there is little effect of preventing erythema, and when it exceeds 10% by weight, there is a concern of cosmetic deterioration such as off-flavor, it is not easy to adjust the viscosity of the cosmetic formulation, and when used in excess, it may cause skin irritation.
본 발명의 피부 홍반 방지용 피부 외용제 조성물에 있어서 상기 텐저레틴(tangeretin)을 함유하는 감귤피 추출물은 조성물 총 중량에 대하여 0.001 ~ 10 중량%로 함유될 수 있다. 감귤피 추출물이 0.001 중량% 미만으로 포함되면 항산화 효과가 거의 없다.In the composition for external application for skin for preventing skin erythema of the present invention, the citrus peel extract containing tangeretin may be contained in an amount of 0.001 to 10% by weight based on the total weight of the composition. If the citrus peel extract is contained in an amount of less than 0.001% by weight, there is almost no antioxidant effect.
본 발명의 피부 홍반 방지용 피부 외용제 조성물에 있어서 상기 EGCG를 포함하는 녹차 추출물은 조성물 총 중량에 대하여 0.001 ~ 99.9 중량%로 포함될 수 있다. 녹차 추출물이 0.001 중량% 미만으로 포함되면 홍반 방지 효과가 거의 없다. In the composition for external application for skin for preventing skin erythema of the present invention, the green tea extract including EGCG may be included in an amount of 0.001 to 99.9% by weight based on the total weight of the composition. When the green tea extract is contained in an amount of less than 0.001% by weight, there is little effect of preventing erythema.
본 발명의 피부 홍반 방지용 조성물의 홍반 방지 효과는 텐저레틴을 함유하는 감귤피 추출물 및 EGCG를 함유하는 녹차 추출물의 복합 추출물에서 더 크게 나타나며, 이는 감귤피 추출물과 녹차 추출물의 시너지 효과에 의한 것이다.
The anti-erythema effect of the composition for preventing skin erythema of the present invention is greater in the complex extract of citrus peel extract containing tenseretine and green tea extract containing EGCG, which is due to the synergistic effect of citrus peel extract and green tea extract.
본 발명은 텐저레틴을 유효성분으로 함유하는 피부톤 개선용 피부외용제 조성물에 관한 것이다. 또한 본 발명은 텐저레틴 및 EGCG를 함유하는 피부 피부톤 개선용 피부 외용제 조성물에 관한 것이다. 또한 본 발명은 텐저레틴을 포함하는 감귤피추출물을 유효성분으로 포함하는 피부톤 개선용 피부 외용제 조성물에 관한 것이다. 또한, 본 발명은 텐저레틴을 포함하는 감귤피추출물에 EGCG(Epigallocatechin gallate)를 포함하는 녹차 추출물을 더 포함하는 피부톤 개선용 피부 외용제 조성물에 관한 것이다.The present invention relates to a composition for external application for skin for improving skin tone containing tenseretin as an active ingredient. In addition, the present invention relates to a composition for external application for skin for improving skin tone containing tangeretin and EGCG. In addition, the present invention relates to a composition for external application for skin for improving skin tone, comprising a citrus skin extract containing tangeretin as an active ingredient. In addition, the present invention relates to a composition for external application for skin for improving skin tone further comprising a green tea extract containing EGCG (Epigallocatechin gallate) in a citrus peel extract containing tangeretin.
본 발명의 피부톤 개선용 피부 외용제 조성물에 있어서 상기 텐저레틴은 조성물 총 중량에 대하여 0.001 ~ 20 중량%로 함유할 수 있다. 상기 텐저레틴이 0.001 중량% 미만인 경우 피부톤 개선 효과가 거의 없으며 20 중량%를 초과하는 경우, 조성물의 안정성 및 안전성을 모두 만족할 수 없으며, 비용 대비 효과의 측면에서도 상기 범위로 포함하는 것이 적절할 수 있다.In the composition for external application for skin for improving skin tone of the present invention, the tangeretin may be contained in an amount of 0.001 to 20% by weight based on the total weight of the composition. When the tangeretin is less than 0.001% by weight, there is little effect of improving skin tone, and when it exceeds 20% by weight, both stability and safety of the composition cannot be satisfied, and it may be appropriate to include it in the above range in terms of cost-effectiveness.
본 발명의 피부톤 개선용 피부 외용제 조성물에 있어서 상기 EGCG는 조성물 총 중량에 대하여 0.01 ~ 20 중량%로 함유할 수 있다. 상기 EGCG가 0.01 중량% 미만인 경우 피부톤 개선 효과가 거의 없으며 20 중량%를 초과하는 경우 조성물의 안정성 및 안전성을 모두 만족할 수 없으며, 비용 대비 효과의 측면에서도 상기 범위로 포함하는 것이 적절할 수 있다.In the composition for external application for skin tone improvement of the present invention, the EGCG may be contained in an amount of 0.01 to 20% by weight based on the total weight of the composition. When the EGCG is less than 0.01% by weight, there is little effect of improving skin tone, and when it exceeds 20% by weight, both stability and safety of the composition cannot be satisfied, and it may be appropriate to include in the above range in terms of cost-effectiveness.
본 발명의 피부톤 개선용 피부 외용제 조성물에 있어서 상기 텐저레틴(tangeretin)을 함유하는 감귤피 추출물은 조성물 총 중량에 대하여 0.001 ~ 10 중량%로 함유될 수 있다. 감귤피 추출물이 0.001 중량% 미만으로 포함되면 피부톤 개선 효과가 거의 없다.In the composition for external application for skin for improving skin tone of the present invention, the citrus peel extract containing tangeretin may be contained in an amount of 0.001 to 10% by weight based on the total weight of the composition. If the citrus peel extract is contained in an amount of less than 0.001% by weight, there is little effect of improving skin tone.
본 발명의 피부톤 개선용 피부 외용제 조성물에 있어서 상기 EGCG를 포함하는 녹차 추출물은 조성물 총 중량에 대하여 0.001 ~ 99.9 중량%로 포함될 수 있다. 녹차 추출물이 0.001 중량% 미만으로 포함되면 피부톤 개선 효과가 거의 없다.In the composition for external application for skin for improving skin tone of the present invention, the green tea extract including EGCG may be included in an amount of 0.001 to 99.9% by weight based on the total weight of the composition. When the green tea extract is contained in an amount of less than 0.001% by weight, there is little effect of improving skin tone.
본 발명의 피부톤 개선용 피부 외용제 조성물의 피부톤 개선 효과는 텐저레틴을 함유하는 감귤피 추출물 및 EGCG를 함유하는 녹차 추출물의 복합 추출물에서 더 크게 나타나며, 이는 감귤피 추출물과 녹차 추출물의 시너지 효과에 의한 것이다.The skin tone improvement effect of the composition for external application for skin tone improvement of the present invention is greater in the complex extract of citrus peel extract containing tenseretine and green tea extract containing EGCG, which is due to the synergistic effect of citrus peel extract and green tea extract .
또한, 본 발명의 일 실시예에서 상기 조성물은 피부 탄력 증대, 피부 주름 개선, 혈색 개선, 모공 수축, 피부 자극 완화, 항상성 향상, 슬리밍, 아토피, 항균 향균, 알러지, 탄력, 여드름, 재생, 피지, 노폐물, 각질 개선 효과, 피부 수렴 및 정돈 효과뿐만 아니라 비만, 당뇨 개선용일 수 있으나, 이에 한정되지는 않는다. In addition, in an embodiment of the present invention, the composition may increase skin elasticity, improve skin wrinkles, improve complexion, shrink pores, relieve skin irritation, improve homeostasis, slimming, atopy, antibacterial antibacterial, allergy, elasticity, acne, regeneration, sebum, It may be used for improving obesity and diabetes, as well as waste products, keratin improving effect, skin astringent and tidying effect, but is not limited thereto.
본 발명에 의한 피부 외용제 조성물은 일반적으로 피부 외용에 사용하는 조성물 전반을 포괄하는 개념이며, 예를 들어 화장료 조성물, 약학 또는 건강식품 조성물일 수 있다. The composition for external application for skin according to the present invention is generally a concept encompassing the overall composition used for external application of the skin, and may be, for example, a cosmetic composition, a pharmaceutical composition, or a health food composition.
화장료 조성물로는 예를 들어, 기초 화장료, 메이크업 화장료, 모발용 화장료, 바디용 화장료 등이 있을 수 있고, 그 제형은 특별히 제한되지 않으며, 목적하는 바에 따라 적절히 선택할 수 있다. The cosmetic composition may include, for example, a basic cosmetic, a makeup cosmetic, a hair cosmetic, a body cosmetic, and the like, and the formulation is not particularly limited and may be appropriately selected according to the intended purpose.
예를 들면, 상기 화장료 조성물은 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연화장수, 영양화장수, 로션, 바디로션, 영양 크림, 마사지 크림, 모이스처 크림, 핸드크림, 에센스, 아이 크림, 클렌징 크림, 클렌징 폼, 클렌징 워터, 팩, 젤, 패치, 수중유(O/W)형, 유중수(W/O)형 등의 기초 화장료, 립스틱, 메이크업베이스 또는 파운데이션 등의 색조 화장료, 샴푸, 린스, 바디클렌저, 치약 또는 구강 청정제 등의 세정료, 헤어토닉, 젤 또는 무스 등의 정발제, 양모제 또는 염모제 등의 모발용 화장료 조성물로 제형화 될 수 있다. For example, the cosmetic composition is formulated as a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, and spray. However, it is not limited thereto. More specifically, softening lotion, nourishing lotion, lotion, body lotion, nourishing cream, massage cream, moisture cream, hand cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, gel, patch, oil-in-water Basic cosmetics such as (O/W) type, water-in-oil (W/O) type, color cosmetics such as lipstick, makeup base or foundation, shampoo, conditioner, body cleanser, cleaning agent such as toothpaste or mouthwash, hair tonic, It can be formulated as a hair cosmetic composition such as a hairdressing agent such as gel or mousse, a woolen agent, or a hair dye.
상기 화장료 조성물은 화장품학적으로 허용가능한 매질 또는 기제를 함유한다. 이는 국소적용에 적합한 모든 제형으로, 예를 들면 용액, 겔, 고체 또는 반죽 무수 생성물, 수상에 유상을 분산시켜 얻은 에멀젼, 현탁액, 마이크로에멀젼, 마이크로캡슐, 미세과립구 또는 이온형(리포좀) 및/또는 비이온형의 소낭 분산제의 형태로, 또는 크림, 스킨, 로션, 파우더, 연고, 스프레이 또는 콘실 스틱의 형태로 제공될 수 있다. 이들 조성물은 당해 분야의 통상적 방법에 따라 제조될 수 있다.The cosmetic composition contains a cosmetically acceptable medium or base. These are all formulations suitable for topical application, e.g. solutions, gels, solid or paste anhydrous products, emulsions obtained by dispersing the oil phase in an aqueous phase, suspensions, microemulsions, microcapsules, microgranules or ionic (liposomes) and/or It may be provided in the form of a nonionic vesicle dispersant, or in the form of a cream, skin, lotion, powder, ointment, spray or conceal stick. These compositions can be prepared according to conventional methods in the art.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or emulsion, a solvent, solubilizer or emulsifier is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of ,3-butyl glycol oil, glycerol aliphatic esters, polyethylene glycol or sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, liquid diluents such as water, ethanol or propylene glycol as carrier components, ethoxylated isostearyl alcohol, suspensions such as polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters, microcrystals Sex cellulose, aluminum metahydroxide, bentonite, agar or trakant, etc. can be used.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, trakant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide, etc. may be used as a carrier component. Can.
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder may be used as a carrier component. In particular, in the case of a spray, additionally chlorofluorohydrocarbon, propane /Propellant such as butane or dimethyl ether.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다. When the formulation of the present invention is a surfactant-containing cleansing, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivatives, methyltaurate, sarcosinate, fatty acid amide as a carrier component Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
본 발명의 일 실시태양에서, 상기 화장료 조성물에 추가적으로 점증제를 함유할 수 있다. 본 발명의 화장료 조성물에 포함되는 점증제는 메틸 셀룰로스, 카르복시 메틸 셀룰로스, 카르복시 메틸 하이드록시 구아닌, 하이드록시 메틸 셀룰로스, 하이드록시에틸셀룰로스, 카르복시 비닐 폴리머, 폴리쿼터늄, 세테아릴 알콜, 스테아릭산, 카라기난 등을 사용할 수 있으며, 바람직하게는 카르복시 메틸 셀룰로스, 카르복시 비닐 폴리머, 폴리쿼터늄 중에서 1종 이상을 사용할 수 있으며, 가장 바람직하게는 카르복시 비닐 폴리머가 될 수 있다. In one embodiment of the present invention, a thickener may be additionally included in the cosmetic composition. Thickeners included in the cosmetic composition of the present invention are methyl cellulose, carboxy methyl cellulose, carboxy methyl hydroxy guanine, hydroxy methyl cellulose, hydroxyethyl cellulose, carboxy vinyl polymer, polyquaternium, cetearyl alcohol, stearic acid, Carrageenan or the like may be used, preferably at least one of carboxy methyl cellulose, carboxy vinyl polymer, and polyquaternium may be used, and most preferably carboxy vinyl polymer may be used.
본 발명의 일 실시태양에서 상기 화장료 조성물은 필요에 따라 적절한 각종의 기제와 첨가제를 함유할 수 있으며, 이들 성분의 종류와 양은 발명자에 의해 용이하게 선정될 수 있다. 필요에 따라 허용 가능한 첨가제를 함유할 수 있으며, 예를 들면, 당업계에 통상적인 방부제, 색소, 첨가제 등의 성분을 추가로 포함할 수 있다. 방부제는 구체적으로 페녹시에탄올(Phenoxyethanol) 또는 1,2-헥산디올 (1,2-Hexanediol) 등이 될 수 있고, 색소는 인공향료 등이 될 수 있다.In one embodiment of the present invention, the cosmetic composition may contain a variety of suitable bases and additives as necessary, and the types and amounts of these ingredients can be easily selected by the inventor. It may contain acceptable additives as needed, and for example, it may further include components such as preservatives, colors, additives, etc. that are common in the art. The preservative may be specifically phenoxyethanol or 1,2-hexanediol, and the color may be an artificial fragrance.
그리고, 본 발명의 일 실시태양에서 화장료 조성물은 수용성 비타민, 유용성 비타민, 고분자 펩티드, 고분자 다당, 스핑고 지질 및 해초 엑기스로 이루어진 군에서 선택된 조성물을 포함할 수 있다. 이외에 첨가해도 되는 배합 성분으로서는 유지 성분, 보습제, 에몰리엔트제, 계면 활성제, 유기 및 무기 안료, 유기 분체, 자외선 흡수제, 방부제, 살균제, 산화 방지제, 식물 추출물, pH 조정제, 알콜, 색소, 향료, 혈행 촉진제, 냉감제, 제한(制汗)제, 정제수 등을 들 수 있다.And, in one embodiment of the present invention, the cosmetic composition may include a composition selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides, sphingo lipids, and seaweed extract. Other ingredients that may be added include fats and oils, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, fungicides, antioxidants, plant extracts, pH adjusters, alcohols, pigments, fragrances, Blood circulation accelerators, cold sensation agents, restrictors, and purified water.
또한, 이외에 첨가해도 되는 배합 성분은 이에 한정되는 것은 아니며, 또, 상기 어느 성분도 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 배합 가능하다.In addition, the blending components that may be added are not limited thereto, and any of the above components can be blended within a range that does not impair the object and effect of the present invention.
본 발명의 일 실시예에서 약학 조성물은 상용되는 무기 또는 유기의 담체를 가하여 고체, 반고체 또는 액상의 형태로 비경구 투여제로 제제화 할 수 있다. 상기 비경구 투여를 위한 제재로는 점적제, 연고, 로션, 겔, 크림, 패취, 스프레이, 현탁제 및 유제로 이루어진 군에서 선택되는 경피 투여형 제형일 수 있으나, 이에 제한되지 않는다.In one embodiment of the present invention, the pharmaceutical composition may be formulated as a parenteral administration in a solid, semi-solid or liquid form by adding a commercially available inorganic or organic carrier. The preparation for parenteral administration may be a transdermal dosage form selected from the group consisting of drops, ointments, lotions, gels, creams, patches, sprays, suspensions and emulsions, but is not limited thereto.
각 제형에 의한 피부 외용제 조성물에 있어서, 상기한 본 발명의 조성물 이외의 다른 성분들을 기타 피부 외용제의 제형 또는 사용 목적 등에 따라 당업자가 어려움 없이 적의 선정하여 배합할 수 있으며, 이 경우 다른 원료와 동시에 적용할 경우 상승효과가 일어날 수 있다.In the composition for external application for skin by each formulation, other ingredients other than the composition of the present invention described above can be appropriately selected and blended without difficulty by those skilled in the art according to the formulation or purpose of use of the external application for skin. If you do, a synergistic effect can occur.
또한, 본 발명에 의한 조성물이 약학 조성물로 사용될 경우에, 방부제, 안정화제, 수화제 또는 유화 촉진제, 삼투업 조절을 위한 염 또는 완충제 등의 약학적 보조제 및 기타 치료적으로 유용한 물질을 추가로 함유할 수 있으며, 통상적인 방법에 따라 다양한 경구 또는 비경구 투여 형태로 제형화할 수 있다. In addition, when the composition according to the present invention is used as a pharmaceutical composition, it may further contain pharmaceutical adjuvants such as preservatives, stabilizers, hydrating agents or emulsifying accelerators, salts or buffers for controlling osmotic uptake, and other therapeutically useful substances. It may be formulated in various oral or parenteral dosage forms according to a conventional method.
유효성분의 실제 투여량은 증상의 중증도, 선택된 투여 경로, 대상의 연령, 성별, 체중 및 건강상태 등의 여러 관련 인자에 비추어 결정되어야 하는 것으로 이해되어야 한다.It should be understood that the actual dosage of the active ingredient should be determined in light of several related factors such as the severity of symptoms, the route of administration chosen, the age, sex, weight and health status of the subject.
일반적으로 유효성분의 투여량은 0.001mg/kg/일 내지 대략 2000mg/kg/일의 범위이다. 더 바람직한 투여량은 0.5mg/kg/일 내지 2.5mg/kg/일이다.
In general, the dosage of the active ingredient is in the range of 0.001 mg/kg/day to about 2000 mg/kg/day. A more preferred dosage is from 0.5 mg/kg/day to 2.5 mg/kg/day.
이하, 본 발명의 실시예, 비교예 및 시험예를 참조하여 본 발명을 상세히 설명한다. 이들은 오로지 본 발명을 보다 구체적으로 설명하기 위해 예시적으로 제시한 것일 뿐, 본 발명의 범위가 이 실시예, 비교예 및 시험예에 의해 제한되지 않는다는 것은 당업계에서 통상의 지식을 가지는 자에 있어서 자명할 것이다.Hereinafter, the present invention will be described in detail with reference to Examples, Comparative Examples and Test Examples of the present invention. These are only provided by way of example to explain the present invention in more detail, the scope of the present invention is not limited by these examples, comparative examples and test examples for those skilled in the art It will be self-evident.
[참고예 1] 감귤피 추출물의 제조[Reference Example 1] Preparation of citrus peel extract
감귤피를 정제수로 세척한 후, 건조 과정을 거친다. 물기가 제거된 감귤피를 분쇄하여 40~48시간간 실온에서 냉침 추출법을 통해 유효성분을 추출한다. 추출한 내용물을 250μm mesh로 1차 여과한 후, 원심분리과정을 통해 상층액을 취한다. 그 내용물을 다시 3μm, 1μm, 0.5μm mesh의 여과지로 순차적으로 여과한다. 1,3- 부틸렌글라이콜 (Butylene glycol) 10%, 페녹시에탄올(phenoxyethanol) 0.5%, 에틸헥실글리세린(Ethylhexylglycerin) 0.05%를 추가하고, 다시 0.2~0.3 μm 여과지로 여과하여 감귤피 추출물을 얻는다.
After washing the citrus peel with purified water, it goes through a drying process. The dried citrus peel is crushed and the active ingredient is extracted through cold needle extraction at room temperature for 40 to 48 hours. After the extracted contents are first filtered through a 250 μm mesh, the supernatant is taken through a centrifugation process. The contents are again filtered sequentially with filter papers of 3 μm, 1 μm, and 0.5 μm mesh. 1,3-Butylene glycol (10%), phenoxyethanol (phenoxyethanol) 0.5%, ethylhexylglycerin (Ethylhexylglycerin) 0.05% was added, and filtered through 0.2~0.3 μm filter paper to obtain a citrus peel extract. .
[참고예 2] 녹차 추출물의 제조[Reference Example 2] Preparation of green tea extract
녹차잎을 정제수로 세척한 후, 건조 과정을 거친다. 물기가 제거된 녹차잎을 분쇄하여 40~48시간간 실온에서 냉침 추출법을 통해 유효성분을 추출한다. 추출한 내용물을 250μm mesh로 1차 여과한 후, 원심분리과정을 통해 상층액을 취한다. 그 내용물을 다시 3μm, 1μm, 0.5μm mesh의 여과지로 순차적으로 여과한다. 1,3- 부틸렌글라이콜 (Butylene glycol) 10%, 페녹시에탄올(phenoxyethanol) 0.5%, 에틸헥실글리세린(Ethylhexylglycerin) 0.05%를 추가하고, 다시 0.2~0.3 μm 여과지로 여과하여 녹차 추출물을 얻는다.
After washing green tea leaves with purified water, it goes through a drying process. The dried green tea leaves are pulverized and the active ingredients are extracted through cold needle extraction at room temperature for 40 to 48 hours. After the extracted contents are first filtered through a 250 μm mesh, the supernatant is taken through a centrifugation process. The contents are again filtered sequentially with filter papers of 3 μm, 1 μm, and 0.5 μm mesh. 1,3-Butylene glycol (10%), phenoxyethanol (phenoxyethanol) 0.5%, ethylhexylglycerin (Ethylhexylglycerin) was added 0.05%, and filtered through 0.2 ~ 0.3 μm filter paper to obtain green tea extract.
[참고예 3] 텐저레틴의 준비[Reference Example 3] Preparation of tangeretin
본 발명에서 사용되는 텐저레틴은 시그마-알드리치사(SigmaAldrich; Tangeretin)에서 구매하였다.
Tangeretin used in the present invention was purchased from Sigma-Aldrich (Tangeretin).
[참고예 4] EGCG의 준비[Reference Example 4] Preparation of EGCG
본 발명에서 사용되는 EGCG는 시그마-알드리치사(SigmaAldrich; EGCG)에서 구매하였다.
The EGCG used in the present invention was purchased from Sigma-Aldrich (EGCG).
[시험예 1] 항산화 효과 실험[Test Example 1] Antioxidant Effect Experiment
본 발명에서 사용된 참고예 1~4의 감귤피 추출물, 녹차 추출물, 텐저레틴 및 EGCG의 항산화 효능을 확인하기 위하여, 자유 라디칼인 1,1-디페닐-2-피크릴히드라질(1,1-Diphenyl-2-picrylhydrazyl: 이하 DPPH)을 사용하였다. 당업계에 통상적으로 알려진 항산화제인 비타민 C를 양성대조군으로 사용하였다.In order to confirm the antioxidant efficacy of the citrus peel extract, green tea extract, tangeretin and EGCG of Reference Examples 1 to 4 used in the present invention, 1,1-diphenyl-2-picrylhydrazil (1,1 -Diphenyl-2-picrylhydrazyl: hereinafter DPPH) was used. Vitamin C, an antioxidant commonly known in the art, was used as a positive control.
보라색을 띠고 있는 DPPH는 항산화 물질과 반응을 하게 되면 항산화 물질로부터 수소 전자를 받게 되어 색깔이 변하고 517nm에서의 흡광도가 감소한다. When DPPH, which has a purple color, reacts with an antioxidant, it receives hydrogen electrons from the antioxidant, changes its color, and decreases its absorbance at 517nm.
참고예 1~4의 감귤피 추출물, 녹차 추출물, 텐저레틴 및 EGCG와 비타민 C를 측정하려는 농도에 맞게 에탄올에 녹여 10μL씩 96-well 플레이트에 넣고, 100μM DPPH 용액을 190μL씩 넣어준 다음 30분간 37℃에서 보관하였다. 그리고 스펙트로포토미터(spectrophotometer)를 이용하여 517nm에서의 흡광도를 측정하여 결과를 하기 표 1에 나타내었다. 또한 감귤피 추출물과, 녹차 추출물 및 비타민 C 처리시의 흡광도 값(O.D.) 결과를 도 2에 나타내었으며, The citrus peel extract, green tea extract, tenseretin, EGCG, and vitamin C of Reference Examples 1 to 4 were dissolved in ethanol according to the concentration to be measured and placed in a 96-well plate each of 10 μL, and 190 μL of 100 μM DPPH solution was added, followed by 30 minutes 37 Stored at °C. And the absorbance at 517 nm was measured using a spectrophotometer, and the results are shown in Table 1 below. In addition, the absorbance value (O.D.) result of citrus peel extract, green tea extract and vitamin C treatment is shown in FIG. 2,
감귤피 추출물과 25 ppm, 녹차 추출물 5μM 단독 처리 및 감귤피 추출물 25 ppm 및 녹차 추출물 5μM을 동시에 처리한 경우 시너지 효과와 DPPH의 색상 변화를 도 3에 나타내었다. Fig. 3 shows the synergistic effect and color change of DPPH when the citrus peel extract and 25 ppm, green tea extract 5 μM alone, and the citrus peel extract 25 ppm and green tea extract 5 μM are simultaneously treated.
또한 텐저레틴, EGCG 5μM 단독 처리 및 텐저레틴과 EGCG를 동시 처리시의 흡광도 값과 DPPH 색상 변화를 도 4에 나타내었다.In addition, the absorbance value and DPPH color change when tenseretin and 5 μM of EGCG are treated alone, and when tenseretin and EGCG are simultaneously treated are shown in FIG. 4.
상기 표 1 및 도 2에 나타난 바와 같이, 아무것도 처리하지 않은 대조군과 비교할 때, 녹차 추출물의 EGCG를 사용하였을 때 흡광도(O.D)값이 크게 감소하였고, 텐저레틴을 200ppm으로 사용한 경우는 약 50% 이상 감소하여 우수한 항산화 효과를 가짐을 알 수 있었다. 특히, ECGC 5uM와 텐저레틴을 함께 사용한 경우 흡광도가 80% 이상 감소하여 우수한 시너지 효과를 보임을 알 수 있었으며, 이러한 시너지 효과를 도 3에 구체적으로 나타내었다.
As shown in Table 1 and FIG. 2, when compared with the control group that was not treated with anything, the absorbance (OD) value was significantly reduced when EGCG of green tea extract was used, and about 50% or more when tenseretine was used at 200 ppm. It was found to have an excellent antioxidant effect by decreasing. In particular, when ECGC 5uM and tangeretin were used together, it was found that the absorbance decreased by 80% or more to show an excellent synergistic effect, and this synergistic effect was specifically shown in FIG. 3.
[시험예 2] 홍반 발생 실험[Test Example 2] Erythema occurrence experiment
건강한 성인 40명을 대상으로 피부자극 시험을 실시하였으며, 단 건선(Psoriasis), 여드름(acne), 습진(eczema), 기타 피부병 등의 보유자나 임신, 수유부 또는 피임제, 항히스타민제 등을 복용하고 있는 사람은 피험자 선정에서 제외하였다.Skin irritation tests were conducted on 40 healthy adults, provided that those with psoriasis, acne, eczema, and other skin diseases, pregnant, lactating women, or taking contraceptives, antihistamines, etc. Were excluded from the selection of subjects.
시험물질로는 상기 참고예 1~4를 사용하였으며, 시험물질의 도포는 피험자의 등 부위에 패치 테스트(closed patch test)로 진행하였으며, 도포량은 각각 20μl/챔버(IQ 챔버)로 하였고, 구체적인 시험물질의 농도는 하기 표 3에 제시되어 있다. 24시간 동안 패치를 붙이고 패치를 제거한 다음 30분, 24시간에 검사를 실시하였다. 반응 검사는 CTFA 가이드라인(1981)과Frosch & Kligman(1979)의 검사기준에서 변형된 검사기준인 하기 표 2에 제시된 기준에 의거하여 검사하여, 결과를 하기 표 3에 나타내었다.Reference examples 1 to 4 were used as the test substance, and the application of the test substance was performed by a closed patch test on the back of the subject, and the application amount was each 20 μl/chamber (IQ chamber), and a specific test The concentrations of the substances are shown in Table 3 below. After applying the patch for 24 hours, removing the patch, the test was performed at 30 minutes and 24 hours. The reaction test was tested according to the criteria shown in Table 2 below, which is a modified test standard from the CTFA guideline (1981) and the test standard of Frosch & Kligman (1979), and the results are shown in Table 3 below.
Grade II (경자극 범위) : 3미만
Grade III (중자극 범위) : 5미만
Grade IV (강자극 범위) : 5이상Grade I (no irritation range): Less than 1
Grade II (range of mild irritation): Less than 3
Grade III (medium irritation range): Less than 5
Grade IV (strong irritation range): 5 or more
참고예 1의 감귤피 추출물25ppmGreen tea extract of Reference Example 2 5 μM +
Citrus peel extract of Reference Example 1 25ppm
상기 표 3의 결과에서, 본 발명에 따른 텐저레틴 또는 EGCG는 자극이 매우 적으며, 녹차추출물과 감귤피 추출물을 사용한 경우 보다 현저히 낮은 자극 수준을 나타냄을 확인할 수 있다.
From the results of Table 3, it can be seen that the tangeretin or EGCG according to the present invention exhibits very little stimulation, and a significantly lower stimulation level than when using green tea extract and citrus peel extract.
[실시예 1~4][Examples 1 to 4]
상기 참고예 1~4를 사용하여 하기 표 4의 조성을 갖는 피부톤 개선용 화장료 조성물을 제조하였다. (단위: 중량%)Using the Reference Examples 1 to 4, a cosmetic composition for improving skin tone having the composition of Table 4 was prepared. (Unit:% by weight)
[시험예 3] 안색 개선 평가[Test Example 3] Evaluation of complexion improvement
피부톤 개선 효과를 확인하기 위하여 20~40대의 건강한 여성 60명을 대상으로 10명씩 6개군으로 나누어 실험하였다. 각 군에 실시예 1~4 의 제형을 주고 안면 전체에 고르게 하루 2회씩 4주간 도포하게 한 후, 4주 후 크로마미터(Minolta CM-3500d)를 이용하여 색의 밝기변화(△L)를 측정하여 피부톤 개선 정도를 평가하였으며, 그 결과를 하기 표 5에 나타내었다. 표 5에 기재된 수치는 각 군의 평균치이다.
In order to confirm the effect of improving skin tone, 60 healthy women in their 20s to 40s were divided into 6 groups of 10 each. Each group was given the formulations of Examples 1 to 4 and applied evenly to the entire face twice a day for 4 weeks, and after 4 weeks, the change in color brightness (ΔL) was measured using a chromameter (Minolta CM-3500d). The degree of improvement in skin tone was evaluated, and the results are shown in Table 5 below. The numerical values shown in Table 5 are the average values of each group.
상기 표 5의 결과에서, 유효 성분으로 감귤피추출물과 녹차추출물을 동시에 포함하거나 텐저레틴과 EGCG를 함께 포함한 제형인 실시예 2와 실시예 4의 경우가 △L 값이 높았다. 이를 통해 감귤피추출물과 녹차추출물을 동시에 포함하는 조성물의 피부 명암을 밝게 하는 효과가 매우 뛰어남을 확인할 수 있다. 또한 EGCG 와 텐저레틴을 모두 포함하는 실시예 4의 효과가 가장 우수하다는 결과를 통해 상기 성분들을 모두 포함하면 그 효과가 더욱 상승함을 확인할 수 있다.In the results of Table 5, ΔL values were high in Examples 2 and 4, which were formulations containing both citrus peel extract and green tea extract as active ingredients, or both tangeretin and EGCG. Through this, it can be seen that the effect of brightening the skin contrast of the composition containing the citrus peel extract and the green tea extract at the same time is very excellent. In addition, it can be seen from the result that the effect of Example 4 including both EGCG and tangeretin is the most excellent, and that the effect is further increased when all of the above components are included.
하기에 본 발명에 따른 화장료 조성물 및 약학 조성물의 제형예를 설명하나, 하기 예시 이외에도 여러 가지 제형으로 응용 가능하며, 이는 본 발명을 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.
Hereinafter, examples of formulations of the cosmetic composition and pharmaceutical composition according to the present invention are described, but can be applied in various formulations other than the following examples, which are intended to be described in detail only, not to limit the present invention.
[제형예 1] 유연 화장수(스킨 로션)[Formulation Example 1] Flexible lotion (skin lotion)
하기 표 6에 기재된 조성에 따라 통상적인 방법으로 유연 화장수를 제조하였다.According to the composition shown in Table 6 below, a flexible lotion was prepared by a conventional method.
[제형예 2] 영양 화장수(밀크 로션)[Formulation Example 2] Nourishing lotion (milk lotion)
하기 표 7에 기재된 조성에 따라 통상적인 방법으로 영양 화장수를 제조하였다.A nutrient lotion was prepared by a conventional method according to the composition shown in Table 7 below.
[제형예 3] 영양 크림[Formulation Example 3] Nourishing Cream
하기 표 8에 기재된 조성에 따라 통상적인 방법으로 영양 크림을 제조하였다. A nourishing cream was prepared by a conventional method according to the composition shown in Table 8 below.
[제형예 4] 맛사지 크림[Formulation Example 4] Massage Cream
하기 표 9에 기재된 조성에 따라 통상적인 방법으로 맛사지 크림을 제조하였다. A massage cream was prepared by a conventional method according to the composition shown in Table 9 below.
[제형예 5] 팩[Formulation Example 5] Pack
하기 표 10에 기재된 조성에 따라 통상적인 방법으로 팩을 제조하였다. A pack was prepared by a conventional method according to the composition shown in Table 10 below.
[제형예 6] 국소 투여용 약제(패취제)[Formulation Example 6] Drug for topical administration (patch)
하기 표 11에 기재된 조성에 따라 통상적인 방법으로 패취제를 제조하였다. According to the composition shown in Table 11 to prepare a patch by a conventional method.
본 발명이 속한 분야에서 통상의 지식을 가진 자라면 상기 내용을 바탕으로 본 발명의 범주 내에서 다양한 응용 및 변형을 행하는 것이 가능할 것이다.Those skilled in the art to which the present invention pertains will be able to make various applications and modifications within the scope of the present invention based on the above.
이상으로 본 발명의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.
As described above, a specific part of the present invention has been described in detail, and it is clear that this specific technique is only a preferred embodiment for those of ordinary skill in the art, and the scope of the present invention is not limited thereto. Therefore, it will be said that the substantial scope of the present invention is defined by the appended claims and their equivalents.
Claims (30)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG11201402849PA SG11201402849PA (en) | 2011-12-16 | 2012-12-17 | Composition containing tangeretin for external application to the skin |
| CN201280061424.8A CN103987385A (en) | 2011-12-16 | 2012-12-17 | Composition containing tangeretin for external application to the skin |
| CN201710166759.0A CN107412031B (en) | 2011-12-16 | 2012-12-17 | Skin external composition containing hesperetin |
| PCT/KR2012/011009 WO2013089533A1 (en) | 2011-12-16 | 2012-12-17 | Composition containing tangeretin for external application to the skin |
| SG10201604847SA SG10201604847SA (en) | 2011-12-16 | 2012-12-17 | Composition containing tangeretin for external application to the skin |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20110136181 | 2011-12-16 | ||
| KR1020110136181 | 2011-12-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20130069512A KR20130069512A (en) | 2013-06-26 |
| KR102142311B1 true KR102142311B1 (en) | 2020-08-10 |
Family
ID=48864772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020120146540A KR102142311B1 (en) | 2011-12-16 | 2012-12-14 | Skin external composition comprising tangeretin |
Country Status (3)
| Country | Link |
|---|---|
| KR (1) | KR102142311B1 (en) |
| CN (2) | CN107412031B (en) |
| SG (2) | SG11201402849PA (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130088912A (en) * | 2012-01-31 | 2013-08-09 | (주)아모레퍼시픽 | Skin external composition containing tangeretin and egcg |
| TWI754037B (en) * | 2017-04-03 | 2022-02-01 | 大江生醫股份有限公司 | Composition containing plant extracts and uses thereof for reducing fat |
| CN108653478A (en) * | 2017-09-06 | 2018-10-16 | 四川云想科技有限公司 | A kind of antibacterial anti-inflammatory externally-used embrocation and its preparation method and application |
| KR102152584B1 (en) * | 2017-11-06 | 2020-09-08 | (주)아모레퍼시픽 | cosmetic composition for skin aging and moisturizing including extract of Jejudo hydrangea |
| CN108464949B (en) * | 2018-05-03 | 2021-04-20 | 上海璞萃生物科技有限公司 | Antioxidant whitening composition and application thereof |
| CN110833119A (en) * | 2019-10-30 | 2020-02-25 | 李佳璘 | Application of citrus fruit extract in livestock breeding and preparation method thereof |
| EP4057834A4 (en) * | 2019-11-15 | 2023-12-06 | DuPont Nutrition Biosciences ApS | Process for reducing oxidation of a foodstuff and related compositions |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2699818B1 (en) * | 1992-12-24 | 1995-02-03 | Oreal | Cosmetic or pharmaceutical composition containing in combination a polyphenol and an extract of gingko. |
| US20070003536A1 (en) * | 2000-11-21 | 2007-01-04 | Zimmerman Amy C | Topical skin compositions, their preparation, and their use |
| CN100539988C (en) * | 2003-06-27 | 2009-09-16 | 株式会社太平洋 | The self aggregation polymer nano granules and the externally-applied liniment that contains this nano-particle that contain physiologically active ingredient |
| FR2869229B1 (en) * | 2004-04-26 | 2006-08-25 | Sederma Soc Par Actions Simpli | USE OF A INDUCER OF UGT BY TOPIC |
| JP4326418B2 (en) | 2004-07-16 | 2009-09-09 | 株式会社東京精密 | Film peeling method and film peeling apparatus |
| KR20060058621A (en) * | 2004-11-25 | 2006-05-30 | 정찬규 | The bio-beauty pack to be made up yellow soil with hamcho(salicornia herbacea)and a method of production |
| JP5192380B2 (en) * | 2005-09-08 | 2013-05-08 | 株式會社アモーレパシフィック | Skin external preparation composition for preventing skin aging |
| KR101405417B1 (en) * | 2007-07-19 | 2014-06-12 | (주)아모레퍼시픽 | Manufacturing Method of Skin External Composition Controlled Transepidermal Absorption Using Phase Transition of Lysophospholipids based Colloid |
| CN101850010B (en) * | 2010-05-25 | 2013-06-12 | 广东药学院 | Active extract of citrus peels as well as extraction process and application thereof |
-
2012
- 2012-12-14 KR KR1020120146540A patent/KR102142311B1/en active IP Right Grant
- 2012-12-17 SG SG11201402849PA patent/SG11201402849PA/en unknown
- 2012-12-17 SG SG10201604847SA patent/SG10201604847SA/en unknown
- 2012-12-17 CN CN201710166759.0A patent/CN107412031B/en active Active
- 2012-12-17 CN CN201280061424.8A patent/CN103987385A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN107412031B (en) | 2021-01-05 |
| CN107412031A (en) | 2017-12-01 |
| CN103987385A (en) | 2014-08-13 |
| SG11201402849PA (en) | 2014-10-30 |
| KR20130069512A (en) | 2013-06-26 |
| SG10201604847SA (en) | 2016-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101677254B1 (en) | Composition for beauty of skin containing coumestrol or germinated soy bean extract with coumestrol | |
| KR102142311B1 (en) | Skin external composition comprising tangeretin | |
| KR20130088912A (en) | Skin external composition containing tangeretin and egcg | |
| KR102015173B1 (en) | Low irritating cosmetic composition for skin whitening | |
| KR101781466B1 (en) | Antioxidant composition for skin external application comprising nelumbo nucifera flowers extract and prunus mume fruits extract | |
| KR102525467B1 (en) | Skin external application composition for anti-aging containing Rhodotypos scandens extract | |
| KR102300581B1 (en) | Compositions for improving skin conditions comprising plant extracts or fractions thereof | |
| KR101744889B1 (en) | Composition for Anti-oxidation, Whitening and Wrinkles protection | |
| KR20200075495A (en) | Low irritating cosmetic composition for skin whitening comprising albutin and extract of Euterpe oleracea fruit | |
| KR102169463B1 (en) | Cosmetic composition for improving skin troubles | |
| KR102214985B1 (en) | Compositions for improving skin conditions comprising plant extracts or fractions thereof | |
| KR102303644B1 (en) | Face cosmetics fermentation composition comprising vegetable mixed extract and tumeric extract | |
| KR101419588B1 (en) | Composition for Moisturizing Skin Comprising Ginseng Oil as Active Ingredient | |
| KR100638053B1 (en) | Cosmetic composition for abirritating skin containing extract of rumex crispus as active ingredient | |
| KR102226179B1 (en) | Cosmetic Compositions for Anti-aging Comprising Extracts of Plants | |
| KR102525901B1 (en) | Skin external application composition for anti-aging containing Phlox subulata extract | |
| KR102711814B1 (en) | Skin external application composition for anti-aging | |
| KR20090105222A (en) | The cosmetic composition for the reduction of skin pores | |
| KR102027647B1 (en) | Low irritating cosmetic composition for skin whitening comprising albutin | |
| KR101436819B1 (en) | Cosmetic composition for moisturing, soothing skin and improving acne | |
| KR101419587B1 (en) | Composition for Promoting Regeneration of Skin Comprising Ginseng Oil as Active Ingredient | |
| KR102628074B1 (en) | skin external application composition for anti-aging containing Luzula capitate extract | |
| KR102689489B1 (en) | A cosmetic compositon comprising chamaecyparis obtuse leaf extracts, andrographis paniculata extract, and astaxanthin as active ingredients | |
| KR102419399B1 (en) | Cica-care cream composition and manufacturing method thereof | |
| KR100909729B1 (en) | Cosmetic composition for preventing and improving acne containing Namsil extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |